Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
NCT04762758Phase 3Active, not recruiting
- Sponsor
- Pharnext
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing PXT3003 with Placebo (2 arms). Primary endpoint: modified Overall Neuropathy Limitations Score at Month 15. Started Mar 2021; status: active, not recruiting.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT04762758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762758.